Neonatal Jaundice

Topic Overview

Summary

Neonatal jaundice is yellowing of the skin and sclera caused by elevated serum bilirubin levels, affecting approximately 60% of term and 80% of preterm infants in the first week of life. [1] While most cases represent benign physiological jaundice that resolves spontaneously, pathological jaundice—characterized by onset within 24 hours, rapid rise, or prolongation beyond 14 days—requires urgent investigation and treatment. Severe unconjugated hyperbilirubinaemia can cause kernicterus, an irreversible form of bilirubin encephalopathy resulting in permanent neurological sequelae including choreoathetoid cerebral palsy, sensorineural deafness, and gaze abnormalities. [2,3] Early recognition, systematic assessment using bilirubin nomograms, and timely intervention with phototherapy or exchange transfusion have dramatically reduced kernicterus incidence in high-resource settings from 1 in 10,000 to approximately 1 in 100,000 live births. [4,5]

Key Facts

• Incidence: Visible jaundice in 60% of term and 80% of preterm infants; clinically significant hyperbilirubinaemia requiring treatment in 5-10% [1]
• Physiological jaundice: Appears after 24 hours, peaks at 3-5 days, resolves by 2 weeks in term infants (3 weeks in preterm)
• Pathological features: Onset less than 24 hours (always pathological), rate of rise > 8.5 μmol/L/hr (0.5 mg/dL/hr), prolongation > 14 days (term) or > 21 days (preterm)
• Kernicterus: Preventable catastrophic complication causing permanent brain damage with mortality or severe disability [2,3]
• Treatment modalities: Phototherapy (90-95% of cases), exchange transfusion (severe/refractory cases), IVIG (immune-mediated haemolysis)
• Conjugated hyperbilirubinaemia: Always pathological; biliary atresia is a surgical emergency requiring Kasai portoenterostomy before 60 days for optimal outcomes [6]
• Global burden: Neonatal jaundice contributes to estimated 114,000 neonatal deaths annually worldwide and 63,000 survivors with moderate-severe disability [1]

Clinical Pearls

Jaundice within first 24 hours of life is ALWAYS pathological—investigate immediately for haemolysis (Rh/ABO incompatibility, G6PD deficiency), sepsis, or hereditary spherocytosis. These infants require urgent bilirubin measurement and senior review.

Conjugated hyperbilirubinaemia is NEVER physiological—pale stools + dark urine indicate biliary obstruction. Measure conjugated/direct bilirubin urgently; if > 25 μmol/L, refer immediately to paediatric hepatology to exclude biliary atresia (Kasai procedure most successful less than 60 days of age). [6]

Plot every bilirubin on the appropriate nomogram—visual assessment alone is unreliable, particularly in dark-skinned infants and under phototherapy. Use gestation-specific treatment thresholds; preterm infants require lower thresholds due to increased susceptibility to bilirubin neurotoxicity. [7,8]

Acute bilirubin encephalopathy is a medical emergency—lethargy, poor feeding, hypotonia progressing to hypertonia, high-pitched cry, or opisthotonus warrant immediate intensive phototherapy and preparation for exchange transfusion regardless of bilirubin level. [2,3]

Bilirubin/albumin ratio predicts kernicterus risk better than total bilirubin alone—free (unbound) bilirubin crosses the blood-brain barrier. Sick preterm infants with low albumin (less than 25 g/L), acidosis, or sepsis develop neurotoxicity at lower total bilirubin levels. [9,10]

Why This Matters Clinically

Neonatal jaundice is among the most common reasons for hospital readmission in the neonatal period and remains a significant cause of preventable brain damage globally. [1,4] Every healthcare professional caring for newborns must competently recognize red flags, correctly interpret bilirubin nomograms, distinguish unconjugated from conjugated hyperbilirubinaemia, initiate timely phototherapy, and identify infants requiring escalation to exchange transfusion. Delayed recognition of conjugated hyperbilirubinaemia, particularly from biliary atresia, results in progressive liver cirrhosis and necessitates liver transplantation—outcomes that are preventable with early diagnosis. The global disparity in kernicterus rates (virtually eliminated in developed nations but persistent in low-resource settings) underscores the critical importance of systematic screening, evidence-based treatment thresholds, and accessible phototherapy. [1,5]

---

Visual Summary

Visual assets to be added:

• Bilirubin metabolism pathway (haem catabolism → unconjugated bilirubin → hepatic conjugation → biliary excretion)
• NICE/AAP bilirubin nomograms (gestation-specific phototherapy and exchange transfusion thresholds)
• Phototherapy setup (overhead LED lights, biliblanket, eye protection)
• Kramer's rule (cephalocaudal progression of jaundice)
• Stool colour chart for biliary atresia screening
• Acute bilirubin encephalopathy clinical progression diagram
• Kernicterus pathology (basal ganglia involvement on MRI)

---

Epidemiology

Incidence & Prevalence

• Visible jaundice: Affects 60% of term newborns and approximately 80% of preterm infants in the first week [1]
• Clinically significant hyperbilirubinaemia: Requiring phototherapy in 5-10% of newborns; exchange transfusion in 0.5-2 per 1,000 [4,7]
• Kernicterus: Estimated incidence 0.4-2.7 per 100,000 live births in developed countries (higher in preterm and low-resource settings) [4,5]
• Acute bilirubin encephalopathy: Approximately 1 in 10,000 jaundiced infants; higher in resource-limited settings without systematic screening [1]
• Biliary atresia: 1 in 10,000-18,000 live births; most common indication for paediatric liver transplantation [6]
• G6PD deficiency-related severe jaundice: Major contributor in Mediterranean, Middle Eastern, and Asian populations where G6PD prevalence reaches 5-25% [11]

Demographics & Geographic Variation

• Gestation: Preterm infants have higher incidence (80% vs 60%) and develop jaundice at lower bilirubin levels due to immature hepatic conjugation and increased blood-brain barrier permeability [8]
• Ethnicity: Higher rates in East Asian (Chinese, Japanese, Korean) and Native American populations; lower in African populations [1,12]
• Gender: Males have slightly higher incidence than females (male-to-female ratio approximately 1.2-1.5:1) [12]
• Geographic burden: Estimated 481,000 late preterm and term infants develop severe hyperbilirubinaemia annually worldwide; South Asia and sub-Saharan Africa account for two-thirds of cases [1]

Risk Factors for Severe Hyperbilirubinaemia

Major Risk Factors

Minor Risk Factors

Protective Factors

• Black African ethnicity: Lower bilirubin levels compared to other populations [12]
• Formula feeding: More frequent stools reduce enterohepatic circulation (but breastfeeding remains strongly recommended)
• Term gestation: Mature hepatic conjugation enzymes

---

Pathophysiology

Normal Bilirubin Metabolism

Bilirubin Production

1. Haem catabolism: Senescent red blood cells (RBCs) are phagocytosed by reticuloendothelial system (spleen, liver, bone marrow)
2. Haem oxygenase: Converts haem → biliverdin (green pigment) + carbon monoxide + iron
3. Biliverdin reductase: Reduces biliverdin → unconjugated (indirect) bilirubin
4. Transport: Unconjugated bilirubin is hydrophobic and insoluble; binds to albumin for transport to liver
5. Normal production: Neonates produce 6-10 mg/kg/day bilirubin (2-3× adult production) due to higher RBC mass and shorter RBC lifespan [13]

Hepatic Conjugation

1. Hepatocellular uptake: Unconjugated bilirubin dissociates from albumin and enters hepatocytes via carrier-mediated transport
2. UGT1A1 enzyme: Uridine diphosphate glucuronosyltransferase 1A1 conjugates bilirubin with glucuronic acid
3. Water-soluble conjugation: Creates bilirubin diglucuronide (direct/conjugated bilirubin), which is water-soluble
4. Biliary excretion: Conjugated bilirubin actively transported into bile canaliculi via MRP2 (multidrug resistance protein 2)
5. Intestinal excretion: Bile flows into duodenum → bacterial β-glucuronidase converts conjugated bilirubin → urobilinogen → stercobilin (brown stool colour)

Why Neonates Are Uniquely Susceptible to Jaundice

Increased Bilirubin Production

• Higher RBC mass: Fetal haematocrit 50-60% vs adult 40-45%
• Shorter RBC lifespan: Fetal RBCs survive 70-90 days vs adult 120 days [13]
• Increased enterohepatic circulation: Neonatal gut has high β-glucuronidase activity → deconjugates bilirubin → reabsorption into portal circulation
• Delayed gut colonization: Sterile meconium cannot convert bilirubin to urobilinogen
• Extravascular blood: Cephalhaematoma, bruising, or polycythaemia increase bilirubin load

Decreased Bilirubin Conjugation

• Immature UGT1A1: Activity at birth is only 0.1-1% of adult levels; reaches adult levels by 6-14 weeks [13,14]
• Reduced hepatic uptake: Immature sinusoidal membrane transporter systems
• Genetic polymorphisms: UGT1A1 variants (Gilbert syndrome allele) reduce enzyme activity by 30-70% [14]

Increased Enterohepatic Circulation

• Delayed feeding: Meconium retention increases β-glucuronidase exposure time
• Sterile gut: Absence of bacteria that metabolize bilirubin to urobilinogen
• Breast milk: Contains lipases that enhance β-glucuronidase activity (breast milk jaundice mechanism) [15]

Unconjugated vs Conjugated Hyperbilirubinaemia

Mechanisms of Pathological Jaundice

Unconjugated Hyperbilirubinaemia

A. Increased Production (Haemolysis)

1. Immune-mediated

   • Rh incompatibility: Maternal anti-D antibodies cross placenta → fetal RBC destruction → severe jaundice, anaemia, hydrops fetalis [16]
   • ABO incompatibility: Most common (mother O, baby A/B); usually mild-moderate; positive direct Coombs test [16]
   • Minor blood group incompatibilities: Kell, Duffy, Kidd antigens (rare)

2. RBC membrane defects

   • Hereditary spherocytosis: Spectrin/ankyrin deficiency → spherical RBCs prone to splenic destruction [17]
   • Hereditary elliptocytosis: Usually asymptomatic but can cause neonatal haemolysis

3. RBC enzyme defects

   • G6PD deficiency: X-linked; oxidative stress (infection, drugs, fava beans) causes haemolysis; common in Mediterranean, African, Asian populations [11]
   • Pyruvate kinase deficiency: Autosomal recessive; chronic haemolytic anaemia

4. Other causes

   • Polycythaemia: Maternal diabetes, twin-twin transfusion, delayed cord clamping
   • Sequestrated blood: Cephalhaematoma, subgaleal haemorrhage, intracranial haemorrhage

B. Decreased Conjugation

1. Physiological jaundice: Immature UGT1A1 enzyme (universal in neonates) [13]
2. Breast milk jaundice: Breast milk lipases increase enterohepatic circulation; β-glucuronidase deconjugates bilirubin [15]
3. Crigler-Najjar syndrome:
   • Type I (autosomal recessive): Complete absence of UGT1A1 → severe jaundice, requires lifelong phototherapy, liver transplant
   • Type II (autosomal dominant): Partial UGT1A1 deficiency; responds to phenobarbital
4. Gilbert syndrome: UGT1A1 promoter polymorphism (TA repeat) reduces activity 30-70%; mild unconjugated hyperbilirubinaemia [14]
5. Hypothyroidism: Reduced UGT1A1 activity and delayed gut motility
6. Galactosaemia: Accumulating metabolites inhibit UGT1A1

C. Increased Enterohepatic Circulation

1. Breastfeeding jaundice (early): Inadequate intake → dehydration → concentrated bilirubin → increased reabsorption [15]
2. Breast milk jaundice (late): Breast milk factors (lipases, pregnane-3α,20β-diol) increase intestinal bilirubin reabsorption [15]
3. Intestinal obstruction: Pyloric stenosis, ileus → prolonged bilirubin exposure to β-glucuronidase

Conjugated Hyperbilirubinaemia (Neonatal Cholestasis)

A. Extrahepatic Biliary Obstruction

1. Biliary atresia: Progressive obliteration of extrahepatic bile ducts; requires Kasai portoenterostomy less than 60 days; most common cause of neonatal liver transplantation [6]
2. Choledochal cyst: Congenital bile duct dilatation; surgical excision curative
3. Bile duct stenosis/perforation: Rare; usually post-surgical or traumatic

B. Intrahepatic Cholestasis

1. Neonatal hepatitis: Viral (CMV, HSV, hepatitis B/C), bacterial (E. coli, Listeria), toxoplasma
2. Alagille syndrome: JAG1/NOTCH2 mutation → paucity of bile ducts; cardiac, vertebral, facial, renal abnormalities
3. Progressive familial intrahepatic cholestasis (PFIC): BSEP, MDR3, FIC1 mutations → severe cholestasis, early cirrhosis
4. Alpha-1 antitrypsin deficiency: PiZZ phenotype → hepatocyte injury, cholestasis, early cirrhosis
5. Metabolic disorders: Galactosaemia, tyrosinaemia, mitochondrial disorders, peroxisomal disorders

C. Other Causes

1. TPN cholestasis: Prolonged parenteral nutrition → hepatotoxicity, cholestasis (reduced with lipid emulsion modification)
2. Sepsis: Endotoxin-mediated cholestasis
3. Chromosomal: Trisomy 21, Turner syndrome

Kernicterus Pathophysiology

Mechanism of Neurotoxicity

1. Blood-brain barrier penetration: Unconjugated bilirubin is lipophilic; crosses BBB when:

   • Total bilirubin extremely high (overwhelms albumin binding)
   • Free (unbound) bilirubin elevated due to low albumin, displacement by drugs (sulfonamides, ceftriaxone), or acidosis [9,10]
   • BBB disrupted by prematurity, sepsis, hyperosmolality, asphyxia

2. Neuronal deposition: Preferential deposition in areas with high metabolic activity and lipid content:

   • Basal ganglia: Globus pallidus, subthalamic nucleus → choreoathetosis
   • Brainstem: Cranial nerve nuclei (III, IV, VI, VII, VIII) → gaze palsy, hearing loss
   • Hippocampus: Memory impairment
   • Cerebellum: Ataxia

3. Cellular injury mechanisms: [2,3,10]

   • Mitochondrial dysfunction → impaired oxidative phosphorylation
   • Excitotoxicity → glutamate-mediated neuronal death
   • Apoptosis → caspase activation
   • Inflammation → microglial activation, cytokine release

Clinical Phases of Acute Bilirubin Encephalopathy

Phase 1 (Early, 1-2 days): Reversible if treated

• Lethargy, hypotonia
• Poor feeding, weak suck
• High-pitched cry (cranial nerve involvement)

Phase 2 (Intermediate, day 2-7): Potentially reversible

• Irritability, increased tone (hypertonia)
• Fever without infection
• Opisthotonus (arching)
• Oculogyric crisis (forced upward gaze)
• Seizures

Phase 3 (Advanced, after first week): Irreversible

• Profound stupor or coma
• Apnoea, respiratory failure
• Death or progression to chronic encephalopathy

Chronic Bilirubin Encephalopathy (Kernicterus Sequelae)

Classic tetrad: [2,3]

1. Movement disorder: Choreoathetoid cerebral palsy (athetosis, dystonia)—most characteristic finding
2. Auditory neuropathy: Sensorineural hearing loss (often complete deafness); abnormal auditory brainstem response
3. Oculomotor impairment: Upward gaze palsy, strabismus, nystagmus
4. Dental enamel dysplasia: Green staining of deciduous teeth

Additional sequelae:

• Intellectual disability (variable severity)
• Speech and language delays
• Epilepsy (10-20% of survivors)
• Behavioral and psychiatric disorders

---

Clinical Presentation

Typical Physiological Jaundice

Timeline

• Onset: After 24 hours of life (48-72 hours peak)
• Peak: Day 3-5 in term infants; day 5-7 in preterm
• Resolution: By 2 weeks in term; by 3 weeks in preterm [1,13]

Clinical Features

• Yellow discoloration of skin and sclera
• Cephalocaudal progression (Kramer's rule):
  • "Zone 1: Face and neck (bilirubin ~100 μmol/L or 6 mg/dL)"
  • "Zone 2: Upper trunk (bilirubin ~150 μmol/L or 9 mg/dL)"
  • "Zone 3: Lower trunk and thighs (bilirubin ~200 μmol/L or 12 mg/dL)"
  • "Zone 4: Arms and lower legs (bilirubin ~250 μmol/L or 15 mg/dL)"
  • "Zone 5: Hands and feet (bilirubin > 250 μmol/L or > 15 mg/dL)"
• Otherwise well infant: Normal feeding, normal activity, normal tone
• Normal yellow/green stools, normal urine

Important note: Kramer zones are unreliable for determining treatment need—always measure bilirubin objectively. [7,8]

Pathological Jaundice Presentations

Early-Onset Jaundice (less than 24 hours)

Always pathological—investigate urgently [7]

Differential diagnosis:

1. Rh/ABO haemolytic disease: Positive direct Coombs test, anaemia, hepatosplenomegaly [16]
2. G6PD deficiency: Acute haemolysis, Heinz bodies on blood film, low G6PD enzyme level [11]
3. Hereditary spherocytosis: Family history, spherocytes on film, positive osmotic fragility test [17]
4. Congenital infection: TORCH (toxoplasma, rubella, CMV, HSV), hepatosplenomegaly, thrombocytopenia, petechiae
5. Sepsis: E. coli, group B Streptococcus; unwell infant with temperature instability, poor feeding

Breastfeeding Jaundice (Early Breast Milk Jaundice)

• Onset: First week of life (days 2-5)
• Mechanism: Inadequate breast milk intake → dehydration → increased enterohepatic circulation [15]
• Clinical features: Weight loss > 8-10%, infrequent stools (less than 3/day), concentrated urine
• Management: Improve breastfeeding technique, increase feeding frequency (10-12 feeds/24 hours); usually do NOT need to stop breastfeeding

Breast Milk Jaundice (Late Onset)

• Onset: After 5-7 days, peaks at 2-3 weeks
• Mechanism: Breast milk factors (β-glucuronidase, pregnane-3α,20β-diol) increase enterohepatic circulation [15]
• Clinical features: Otherwise healthy, thriving infant; normal stools; bilirubin usually less than 300 μmol/L (18 mg/dL)
• Natural history: May persist 8-12 weeks but gradually declines; benign
• Diagnosis: Clinical diagnosis; bilirubin drops 50-100 μmol/L within 48 hours if breastfeeding interrupted (diagnostic test—rarely necessary)
• Management: Continue breastfeeding (benefits outweigh risks); phototherapy if bilirubin exceeds threshold

Prolonged Jaundice

Definitions: [7]

• Term infants: Jaundice persisting > 14 days
• Preterm infants: Jaundice persisting > 21 days

Requires mandatory investigation—must exclude conjugated hyperbilirubinaemia and serious pathology

Common causes:

1. Breast milk jaundice (most common—50-60% of cases)
2. Hypothyroidism: Screen with TSH, free T4 (included in newborn screening but timing varies)
3. Urinary tract infection: Urine culture (E. coli can cause unconjugated hyperbilirubinaemia)
4. Conjugated hyperbilirubinaemia: URGENT—see below

Conjugated Hyperbilirubinaemia—URGENT PRESENTATION

Definition: Conjugated bilirubin > 25 μmol/L (> 1.5 mg/dL) OR > 20% of total bilirubin [6,7]

Clinical features suggesting conjugated hyperbilirubinaemia:

• Pale/acholic stools: Chalky white, grey, or pale yellow (use stool colour chart)
• Dark urine: Tea-coloured (conjugated bilirubin excreted renally)
• Hepatomegaly: Firm, enlarged liver
• Splenomegaly: Suggests haemolysis or storage disorder
• Failure to thrive: Poor weight gain, vomiting
• Pruritus: Scratching (in older infants)

CRITICAL: Conjugated hyperbilirubinaemia is NEVER physiological and ALWAYS requires urgent investigation [6]

Differential diagnosis:

1. Biliary atresia (most important time-sensitive diagnosis):

   • Progressive obliteration of extrahepatic bile ducts
   • Kasai portoenterostomy most successful if performed less than 60 days of age [6]
   • After 90 days: Success rate less than 25%; most require liver transplantation
   • Clinical: Well at birth, jaundice develops at 2-6 weeks, pale stools, dark urine, hepatomegaly
   • Investigations: Conjugated hyperbilirubinaemia, normal/mildly elevated transaminases, ultrasound (absent/contracted gallbladder), hepatobiliary scintigraphy (no excretion into bowel)

2. Neonatal hepatitis syndrome:

   • Infectious (CMV, HSV, hepatitis B/C, toxoplasma, rubella, enterovirus, HHV-6)
   • Clinical: May have intrauterine growth restriction, hepatosplenomegaly, petechiae, microcephaly
   • Investigations: TORCH serology, viral PCR, elevated transaminases

3. Metabolic disorders:

   • Galactosaemia: E. coli sepsis, hepatomegaly, cataracts; urine reducing substances positive; galactose-1-phosphate uridyltransferase deficiency
   • Alpha-1 antitrypsin deficiency: PiZZ phenotype; low alpha-1 antitrypsin level
   • Tyrosinaemia type 1: Elevated tyrosine, succinylacetone in urine
   • Bile acid synthesis defects: Elevated urine bile acids, low serum bile acids

4. Alagille syndrome:

   • JAG1 or NOTCH2 mutation; paucity of interlobular bile ducts
   • Dysmorphic facies (prominent forehead, deep-set eyes, pointed chin), cardiac (peripheral pulmonary stenosis), vertebral (butterfly vertebrae), renal, ocular (posterior embryotoxon)

5. Choledochal cyst:

   • Congenital bile duct dilatation
   • Ultrasound diagnostic; surgical excision curative

Red Flags for Acute Bilirubin Encephalopathy

Early warning signs (potentially reversible): [2,3]

• Lethargy, drowsiness
• Hypotonia ("floppy baby")
• Poor feeding, weak suck
• High-pitched, shrill cry

Intermediate signs (urgent exchange transfusion):

• Irritability alternating with lethargy
• Hypertonia (increased muscle tone), arching
• Retrocollis, opisthotonus (severe arching)
• Fever without clear infection source
• Oculogyric crisis (sustained upward deviation of eyes)

Advanced signs (life-threatening):

• Stupor, coma
• Seizures (often subtle: apnoea, eye deviation, cycling movements)
• Apnoea, respiratory failure
• Bradycardia

ANY neurological signs in a jaundiced infant = medical emergency requiring immediate intensive phototherapy and preparation for exchange transfusion [7,8]

---

Clinical Examination

Structured Examination Approach

1. General Inspection

• Colour: Yellow tint to skin and sclera; note cephalocaudal progression (Kramer zones)
• Activity level: Alert and active vs lethargic
• Cry: Normal vs high-pitched or weak
• Tone: Normal vs hypotonic or hypertonic
• Posture: Normal flexed posture vs opisthotonus (arching)

Visual assessment limitations: [7,8]

• Unreliable in dark-skinned infants
• Affected by ambient lighting (daylight, fluorescent, phototherapy)
• Underestimates severity in preterm infants
• Always measure bilirubin objectively—never rely on clinical assessment alone

2. Vital Signs & Anthropometry

• Temperature: Hypothermia or fever (sepsis)
• Heart rate: Tachycardia (anaemia, sepsis, encephalopathy)
• Respiratory rate: Tachypnoea or apnoea
• Weight: Document weight loss from birth (> 10% concerning for dehydration)
• Head circumference: Microcephaly (congenital infection)

3. Systematic Examination

4. Specific Assessments

Stool colour (use validated stool colour chart): [6]

• Normal: Yellow, green, brown
• Abnormal (conjugated hyperbilirubinaemia): Pale, chalky, white, grey (acholic)
• Stool colour charts have > 90% sensitivity for biliary atresia when used correctly

Urine colour:

• Normal: Colourless, pale yellow
• Abnormal: Dark, tea-coloured (bilirubinuria suggests conjugated hyperbilirubinaemia)

Feeding assessment:

• Frequency: less than 8 feeds/24 hours suggests inadequate intake
• Effectiveness: Observe latch, suck-swallow coordination
• Output: less than 3 stools/day in first week suggests insufficient milk

---

Investigations

Universal Screening & First-Line Investigations

Bilirubin Measurement

1. Transcutaneous Bilirubinometry (TcB)

• Method: Non-invasive device measures skin bilirubin via spectral reflectance [18]
• Advantages: Painless, immediate result, reduces blood sampling
• Limitations:
  • Less accurate at bilirubin > 250 μmol/L (> 15 mg/dL)
  • Unreliable after phototherapy started (skin colour changes)
  • Ethnicity-specific calibration may be needed
  • Cannot distinguish conjugated from unconjugated
• Recommendation: Excellent screening tool; confirm with serum bilirubin if TcB > 75th centile or near treatment threshold [7,8]

2. Serum (Total) Bilirubin (SBR/TSB)

• Method: Venous or capillary blood sample; laboratory measurement (gold standard)
• Indications:
  • TcB above 75th percentile for age in hours
  • TcB within 50 μmol/L of treatment threshold
  • After phototherapy initiated (TcB unreliable)
  • Any pathological features (jaundice less than 24h, prolonged, unwell infant)
• Timing: Plot result on hour-specific nomogram (Bhutani curve or NICE threshold graphs) [7,8]

3. Conjugated (Direct) Bilirubin

• Indications:
  • Prolonged jaundice (> 14 days term, > 21 days preterm) [6,7]
  • Pale stools or dark urine
  • Hepatosplenomegaly
  • Failure to thrive
  • Any suspicion of cholestasis
• Interpretation:
  • "Normal: less than 25 μmol/L (less than 1.5 mg/dL) AND less than 20% of total bilirubin"
  • "Pathological: ≥25 μmol/L OR ≥20% of total bilirubin"
  • Conjugated bilirubin ≥25 μmol/L = URGENT referral to paediatric hepatology [6]

Investigations for Pathological Jaundice

Jaundice Within 24 Hours (Always Pathological)

Immediate investigations: [7,16]

1. Full blood count (FBC):

   • Haemoglobin (anaemia suggests haemolysis)
   • Reticulocyte count (elevated in haemolysis; normal 3-7% in newborns)
   • White cell count (neutropenia/neutrophilia in sepsis)
   • Platelets (thrombocytopenia in sepsis, DIC, congenital infection)

2. Blood film:

   • Spherocytes (hereditary spherocytosis)
   • Fragmented cells (DIC, microangiopathy)
   • Heinz bodies (G6PD deficiency after oxidative stress)
   • Nucleated RBCs (haemolysis, intrauterine hypoxia)

3. Blood group (mother AND baby):

   • ABO incompatibility: Mother O, baby A or B (most common immune haemolysis)
   • Rh incompatibility: Mother Rh-negative, baby Rh-positive

4. Direct antiglobulin test (DAT/Coombs test):

   • Positive: Immune-mediated haemolysis (Rh, ABO, minor antigens)
   • Negative: Does NOT exclude ABO incompatibility (30-40% DAT-negative); consider non-immune causes

5. G6PD enzyme level:

   • If high-risk ethnicity (Mediterranean, Middle Eastern, African, Asian) [11]
   • If unexplained haemolysis with negative DAT
   • Note: May be falsely normal during acute haemolysis (reticulocytes have higher G6PD); retest at 3 months if suspicion high

6. Infection screen (if clinically indicated):

   • Blood culture
   • C-reactive protein (CRP)
   • Lumbar puncture (if sepsis suspected)
   • TORCH serology/PCR if features suggest congenital infection

Prolonged Jaundice (> 14 days term, > 21 days preterm)

NICE-recommended investigation panel: [7]

1. Total AND conjugated bilirubin (MANDATORY—must exclude conjugated hyperbilirubinaemia)
2. FBC and blood film
3. Blood group (baby) and DAT (if not previously done)
4. Thyroid function (TSH and free T4): Hypothyroidism causes prolonged jaundice
5. Urine culture: UTI (E. coli) can cause unconjugated hyperbilirubinaemia
6. Liver function tests (if conjugated bilirubin elevated): ALT, AST, GGT, alkaline phosphatase, albumin
7. Stool colour assessment: Use validated stool colour chart

If conjugated bilirubin ≥25 μmol/L: URGENT additional investigations [6]

• Ultrasound abdomen: Gallbladder size/presence, liver echogenicity, bile duct dilatation (choledochal cyst)
• Hepatobiliary scintigraphy (HIDA scan): Assesses biliary excretion (no excretion into bowel suggests biliary atresia)
• Liver biopsy: Differentiates biliary atresia (bile duct proliferation, portal fibrosis) from neonatal hepatitis (giant cell transformation)
• Alpha-1 antitrypsin level and phenotype
• Metabolic screen: Urine reducing substances (galactosaemia), amino acids, organic acids, acylcarnitine profile
• TORCH serology/PCR: CMV urine PCR, toxoplasma, rubella, HSV
• Genetic testing: Alagille syndrome (JAG1/NOTCH2), PFIC genes (if cholestasis persists)

High Bilirubin or Rapidly Rising Bilirubin

Investigations to guide management and identify cause: [7,8]

1. Repeat bilirubin in 4-6 hours: Assess rate of rise (> 8.5 μmol/L/hr or > 0.5 mg/dL/hr concerning)
2. Albumin level: Low albumin (less than 25 g/L) increases free bilirubin and kernicterus risk [9]
3. Blood gas: Acidosis increases bilirubin neurotoxicity
4. Glucose: Hypoglycaemia in sick infants
5. Sepsis workup if clinically indicated
6. Haemolysis screen: As above (FBC, film, DAT, G6PD)

---

Classification & Staging

Classification by Timing

Classification by Bilirubin Type

Classification by Mechanism

Unconjugated Hyperbilirubinaemia

Increased Production

1. Immune haemolysis:

   • Rh incompatibility (anti-D, anti-C, anti-E) [16]
   • ABO incompatibility (mother O, baby A/B) [16]
   • Minor blood group (Kell, Duffy, Kidd, MNS)

2. Non-immune haemolysis:

   • G6PD deficiency [11]
   • Hereditary spherocytosis [17]
   • Hereditary elliptocytosis
   • Pyruvate kinase deficiency

3. Sequestrated blood:

   • Cephalhaematoma
   • Subgaleal haemorrhage
   • Intracranial haemorrhage
   • Extensive bruising

4. Polycythaemia:

   • Maternal diabetes
   • Twin-twin transfusion
   • Intrauterine growth restriction
   • Delayed cord clamping

Decreased Conjugation

1. Physiological: Immature UGT1A1 (universal) [13]
2. Breast milk jaundice: Increased enterohepatic circulation [15]
3. Crigler-Najjar syndrome: Type I (absent UGT1A1), Type II (reduced UGT1A1)
4. Gilbert syndrome: UGT1A1 promoter polymorphism [14]
5. Hypothyroidism: Reduced UGT1A1 activity, delayed gut motility
6. Drugs: Inhibit UGT1A1 (e.g., chloramphenicol)

Increased Enterohepatic Circulation

1. Breastfeeding jaundice: Inadequate intake, dehydration [15]
2. Intestinal obstruction: Pyloric stenosis, ileus, Hirschsprung disease

Conjugated Hyperbilirubinaemia

Biliary Obstruction

1. Biliary atresia [6]
2. Choledochal cyst
3. Bile duct stenosis/perforation
4. Inspissated bile syndrome

Hepatocellular Disease

1. Neonatal hepatitis: CMV, HSV, hepatitis B/C, toxoplasma, rubella, enterovirus
2. Alagille syndrome: JAG1/NOTCH2 mutation
3. Alpha-1 antitrypsin deficiency
4. Progressive familial intrahepatic cholestasis (PFIC)
5. Metabolic: Galactosaemia, tyrosinaemia, mitochondrial, peroxisomal disorders

Other

1. Sepsis: E. coli, group B Streptococcus, Listeria
2. TPN cholestasis
3. Chromosomal: Trisomy 21, Turner syndrome

Treatment Thresholds (NICE/AAP Guidelines)

Phototherapy Thresholds [7,8]

Principles:

• Use gestation-specific nomograms (different thresholds for less than 38 weeks vs ≥38 weeks)
• Plot bilirubin against age in hours (not days)
• Lower thresholds if risk factors present

Risk factors that LOWER phototherapy threshold by ~50 μmol/L:

• Gestation less than 38 weeks
• Clinical evidence of haemolysis (positive DAT, rapid rise)
• G6PD deficiency
• Asphyxia
• Lethargy, temperature instability, sepsis, acidosis
• Albumin less than 25 g/L

Example thresholds (approximate—always use specific nomograms):

• ≥38 weeks, no risk factors: 250-350 μmol/L (15-20 mg/dL) depending on age
• 35-37 weeks or risk factors: 200-300 μmol/L (12-18 mg/dL)
• less than 35 weeks: Lower thresholds; some units use absolute levels (150-200 μmol/L)

Exchange Transfusion Thresholds [7,8]

Usually ~100 μmol/L (6 mg/dL) above phototherapy threshold

Example thresholds:

• ≥38 weeks, no risk factors: 350-450 μmol/L (20-25 mg/dL)
• 35-37 weeks or risk factors: 300-400 μmol/L (18-23 mg/dL)
• less than 35 weeks: 250-350 μmol/L (15-20 mg/dL)

Immediate exchange transfusion regardless of bilirubin level if: [7,8]

• Signs of acute bilirubin encephalopathy (lethargy, hypotonia, poor feeding, hypertonia, opisthotonus, seizures)
• Bilirubin rising despite intensive phototherapy
• Bilirubin exceeds exchange threshold

---

Management

Management Algorithm

Step 1: Assess and Measure Bilirubin

1. Clinical assessment (Kramer zones) + risk factor identification
2. Measure bilirubin objectively: TcB (screening) or serum bilirubin (confirmation)
3. Plot bilirubin on appropriate nomogram for gestational age and postnatal age in hours

Step 2: Determine Management Based on Threshold

Step 3: Investigate Underlying Cause

• Jaundice less than 24 h: Always investigate (FBC, film, DAT, blood groups, G6PD)
• High/rapidly rising bilirubin: As above + infection screen if indicated
• Prolonged jaundice: Conjugated bilirubin (MANDATORY), TFTs, urine culture, stool colour

Step 4: Monitor Response

• Repeat bilirubin 4-6 hourly during phototherapy
• Check rebound bilirubin 12-24 hours after stopping phototherapy (if stopped before 7 days of age)

Step 5: Stopping Phototherapy

• Bilirubin at least 50 μmol/L (3 mg/dL) below treatment threshold
• No evidence of ongoing haemolysis
• Infant feeding well and otherwise healthy

Phototherapy

Mechanism of Action

• Blue light (wavelength 450-490 nm) converts unconjugated bilirubin in skin and superficial capillaries to photoisomers: [19]
  1. Structural isomers (lumirubin): More water-soluble; excreted in bile and urine without conjugation
  2. Configurational isomers: Less toxic; eventually revert to unconjugated form
• Peak absorption: 460 nm (blue-green light)
• Penetration depth: 1-2 mm (superficial skin only)

Types of Phototherapy

1. Conventional Phototherapy

• Single overhead fluorescent or LED light unit
• Irradiance: 8-10 μW/cm²/nm
• Effective for mild-moderate hyperbilirubinaemia

2. Intensive Phototherapy [19]

• Multiple light sources: Overhead + below (biliblanket/fiberoptic pad)
• LED lights preferred (higher irradiance, less heat, longer lifespan)
• Irradiance: > 30 μW/cm²/nm
• Indications: Bilirubin approaching exchange threshold, rapidly rising, haemolysis

3. Fiberoptic Phototherapy (Biliblanket)

• Portable fiberoptic pad placed under infant
• Advantages: Allows holding/feeding, less hyperthermia, no eye protection needed
• Disadvantages: Less effective than overhead lights as monotherapy
• Best use: Combination with overhead lights for intensive phototherapy

Maximizing Phototherapy Efficacy

Increase surface area exposure:

• Remove all clothing except nappy
• Turn infant regularly (2-3 hourly)
• Minimize time out of phototherapy (except for feeding)

Optimize irradiance:

• Use LED lights (higher irradiance than fluorescent)
• Position lights 10-15 cm from infant (closer = higher irradiance, but monitor temperature)
• Ensure lights properly maintained (irradiance decreases over time)

Combination therapy:

• Overhead + underneath (biliblanket) for intensive phototherapy
• Increases surface area exposure and irradiance

Monitoring During Phototherapy [7,19]

Bilirubin monitoring:

• Measure serum bilirubin 4-6 hourly initially
• Once declining: 6-12 hourly
• Stop when bilirubin ≥50 μmol/L below threshold and no ongoing haemolysis

Clinical monitoring:

• Temperature: 4-hourly (risk of hypothermia or hyperthermia)
• Hydration: Monitor urine output, weight; ensure adequate feeding
• Stool frequency: Increased loose green stools (normal phototherapy effect)
• Skin: Bronze baby syndrome (rare; grey-brown discoloration if conjugated hyperbilirubinaemia)

Eye protection:

• Opaque eye shields to prevent retinal damage
• Ensure not covering nares (risk of suffocation)
• Remove during feeding for parent-infant bonding

Fluid management:

• Increase feeds by 10-20% or ensure 150-180 mL/kg/day intake
• Phototherapy increases insensible water loss
• IV fluids rarely needed unless poor oral intake

Complications of Phototherapy

When to Stop Phototherapy

Criteria: [7]

• Bilirubin ≥50 μmol/L (3 mg/dL) below phototherapy threshold
• Bilirubin level stable or declining
• No evidence of ongoing haemolysis (stable haemoglobin, low reticulocyte count)
• Infant feeding well, clinically stable

Rebound bilirubin:

• Common after stopping phototherapy, especially if stopped less than 7 days of age
• Mechanism: Mobilization of bilirubin from tissues, ongoing haemolysis
• Check bilirubin 12-24 hours after stopping phototherapy if:
  • Stopped before 7 days of age
  • Haemolytic disease (Rh, ABO, G6PD)
  • Preterm infant
• Rebound usually mild (less than 25-50 μmol/L increase); rarely requires restarting phototherapy

Exchange Transfusion

Indications [7,8,20]

Absolute indications:

1. Bilirubin at or above exchange threshold (gestation-specific nomogram)
2. Signs of acute bilirubin encephalopathy (ANY neurological signs: lethargy, hypotonia, poor feeding, irritability, hypertonia, opisthotonus, seizures)—EMERGENCY
3. Bilirubin continues rising despite 6 hours of intensive phototherapy
4. Severe anaemia + hyperbilirubinaemia (Hb less than 100 g/L AND bilirubin approaching threshold)

Relative indications:

• Bilirubin rising > 8.5 μmol/L/hr (0.5 mg/dL/hr) despite phototherapy
• Risk factors present (G6PD, low albumin, acidosis, sepsis) AND bilirubin near threshold

Mechanism & Procedure [20]

Principle: Replace infant's blood with donor blood to:

• Remove bilirubin (50-60% reduction immediately; equilibrates to 25-40% reduction after 1-2 hours)
• Remove maternal antibodies (Rh, ABO disease)
• Correct anaemia
• Remove haemolysed/abnormal RBCs

Technique:

1. Double-volume exchange: 160-180 mL/kg (2 × blood volume) exchanged over 2-4 hours
2. Route: Umbilical venous and arterial catheters (or peripheral arterial + central venous)
3. Aliquots: 5-10 mL aliquots withdrawn and replaced (smaller in preterm/sick infants)
4. Blood product: O-negative or type-specific, cross-matched against mother, CMV-negative, irradiated, less than 5-7 days old
5. Location: Neonatal intensive care unit with continuous cardiorespiratory monitoring

Procedural steps:

• Pre-exchange: Check bilirubin, FBC, glucose, calcium, electrolytes, acid-base
• During exchange: Continuous monitoring (HR, BP, SpO₂, temperature); check calcium, glucose, acid-base at intervals
• Post-exchange: Immediate bilirubin, FBC, glucose, calcium; repeat bilirubin in 2-4 hours (equilibration)

Monitoring During Exchange Transfusion [20]

Continuous monitoring:

• ECG (arrhythmias, especially with calcium/potassium shifts)
• Blood pressure
• Oxygen saturation
• Temperature

Laboratory monitoring:

• Before exchange: Bilirubin, FBC, blood group/cross-match, glucose, calcium, electrolytes, acid-base
• During exchange (every 50-100 mL): Calcium (risk of hypocalcaemia), glucose, acid-base
• After exchange: Immediate bilirubin, FBC, glucose, calcium; repeat bilirubin in 2-4 hours

Complications of Exchange Transfusion [20]

Overall morbidity: 5-12% significant adverse events; mortality 0.3-1% (mostly in critically ill infants with underlying conditions) [20]

Post-Exchange Management

• Continue intensive phototherapy (bilirubin will rebound as tissue stores equilibrate)
• Repeat bilirubin 2-4 hours post-exchange (expect 25-40% reduction from pre-exchange level)
• Monitor bilirubin 4-6 hourly; may require repeat exchange if continues rising
• Monitor for complications: Thrombocytopenia, infection, NEC, anaemia
• Repeat exchange transfusion if:
  • Bilirubin rises to within 50-85 μmol/L (3-5 mg/dL) of exchange threshold
  • Signs of bilirubin encephalopathy persist or worsen

Intravenous Immunoglobulin (IVIG)

Mechanism & Evidence [21]

• Blocks Fc receptors on reticuloendothelial cells → reduces haemolysis
• Meta-analysis shows IVIG reduces need for exchange transfusion in Rh and ABO disease (NNT = 3-4)
• Most effective when given early in disease course

Indications [7,21]

• Rh or ABO haemolytic disease with:
  • Bilirubin rising despite phototherapy
  • Bilirubin within 50-100 μmol/L (3-6 mg/dL) of exchange threshold
• Consider in other immune haemolysis (Kell, Duffy)

Dosing

• 0.5-1 g/kg IV over 2-4 hours
• Can repeat once after 12 hours if inadequate response
• Start phototherapy concurrently

Contraindications & Precautions

• IgA deficiency (risk of anaphylaxis)
• Volume overload (give slowly in preterm/cardiac disease)
• Monitor for hypotension, fever, haemolysis (rare)

Treatment of Specific Causes

ABO/Rh Haemolytic Disease [16]

• Phototherapy (usually required)
• IVIG (reduces exchange transfusion need by ~50%)
• Exchange transfusion if bilirubin exceeds threshold or severe anaemia
• Monitor for late anaemia (2-6 weeks): Weekly haemoglobin for 4-6 weeks; transfusion if Hb less than 70-80 g/L

G6PD Deficiency [11]

• Phototherapy (mainstay)
• Avoid oxidative triggers: Drugs (sulfonamides, antimalarials, aspirin, nitrofurantoin), infections (treat promptly), fava beans
• Exchange transfusion if bilirubin exceeds threshold
• Counsel family: Genetic counselling, trigger avoidance, screening of siblings

Crigler-Najjar Syndrome

• Type I (complete UGT1A1 deficiency):
  • Lifelong intensive phototherapy (10-12 hours/day)
  • Liver transplantation (curative; usually in childhood)
  • "Experimental: Gene therapy, hepatocyte transplantation"
• Type II (partial deficiency):
  • Phenobarbital (induces residual UGT1A1 activity; reduces bilirubin 25-50%)
  • Phototherapy for acute episodes
  • Generally benign prognosis

Breast Milk Jaundice [15]

• Continue breastfeeding (benefits outweigh risks)
• Phototherapy if bilirubin exceeds threshold
• Rarely: Interrupt breastfeeding for 24-48 hours to confirm diagnosis (bilirubin drops 50-100 μmol/L)—but NOT routinely recommended
• Reassure parents: Benign condition, resolves by 8-12 weeks, does NOT require stopping breastfeeding

Supportive Care

Feeding Management

• Breastfeeding: Encourage frequent feeding (8-12 times/24 hours) to enhance gut motility and reduce enterohepatic circulation
• Formula supplementation: Consider if weight loss > 8-10% or poor breastfeeding, but prioritize breastfeeding support
• Hydration: Ensure adequate intake (150-180 mL/kg/day); IV fluids rarely needed

Parental Support

• Explain jaundice (common, usually benign, but monitoring essential)
• Encourage bonding during phototherapy (skin-to-skin breaks, feeding)
• Reassure re: phototherapy safety (no long-term harm; eye shields protect eyes)
• Provide clear safety netting: When to seek help (lethargy, poor feeding, pale stools, dark urine)

---

Complications

Acute Complications

Acute Bilirubin Encephalopathy (ABE) [2,3]

Early phase (reversible with urgent treatment):

• Lethargy, hypotonia, poor suck
• High-pitched cry

Intermediate phase:

• Hypertonia, opisthotonus
• Irritability, fever
• Oculogyric crisis

Advanced phase (high mortality/severe disability):

• Stupor, coma
• Seizures, apnoea
• Death or progression to chronic encephalopathy

Management: Emergency intensive phototherapy + exchange transfusion

Bronze Baby Syndrome [19]

• Grey-brown discoloration of skin during phototherapy
• Mechanism: Accumulation of photoisomers in conjugated hyperbilirubinaemia
• Benign: Does NOT require stopping phototherapy; resolves after phototherapy stopped
• Not associated with adverse outcomes

Dehydration

• Increased insensible losses during phototherapy
• Inadequate breastfeeding (breastfeeding jaundice)
• Management: Ensure adequate feeding; IV fluids if severe

Hypocalcaemia

• During exchange transfusion (citrate binding)
• Management: IV calcium gluconate if symptomatic or ionized calcium less than 0.9 mmol/L

Chronic Complications (Kernicterus) [2,3]

Neurological sequelae (classic tetrad):

1. Extrapyramidal movement disorder: Choreoathetoid cerebral palsy, dystonia (most characteristic finding)
2. Auditory neuropathy spectrum disorder: Sensorineural hearing loss (often complete deafness); abnormal auditory brainstem response
3. Oculomotor abnormalities: Upward gaze palsy (most common), strabismus, nystagmus
4. Dental enamel dysplasia: Green staining of deciduous teeth (bilirubin deposition during tooth development)

Additional sequelae:

• Intellectual disability (variable severity; some have normal intelligence)
• Epilepsy (10-20% of survivors)
• Speech and language delays
• Behavioral and psychiatric problems (ADHD, autism spectrum features)

Prognosis: Permanent disability; no curative treatment; prevention is essential [2,3]

Complications of Missed Conjugated Hyperbilirubinaemia

Biliary Atresia [6]

• Progressive liver fibrosis and cirrhosis
• Kasai portoenterostomy:
  • "Success less than 60 days: 60-80% establish bile flow"
  • "Success 60-90 days: 40-50%"
  • "Success > 90 days: less than 25%"
• Without treatment: Death from liver failure by 2 years
• 50-70% eventually require liver transplantation (even after successful Kasai)

Galactosaemia

• Progressive liver failure, cataracts, intellectual disability
• Treatment: Galactose-free diet (life-long)
• Delay in diagnosis → irreversible neurological damage

Tyrosinaemia Type 1

• Acute liver failure, renal tubular dysfunction
• Treatment: Nitisinone + low-tyrosine diet
• Untreated: Liver failure, hepatocellular carcinoma

---

Prognosis & Outcomes

Natural History

Physiological Jaundice [1,13]

• Timeline: Onset 24-72h, peak 3-5 days, resolution by 14 days (term) or 21 days (preterm)
• Prognosis: Benign, self-limiting, no sequelae
• No treatment required if bilirubin below threshold

Breast Milk Jaundice [15]

• Timeline: Onset 5-7 days, peak 2-3 weeks, gradual resolution over 8-12 weeks
• Prognosis: Benign, no neurodevelopmental sequelae
• Management: Continue breastfeeding; phototherapy if bilirubin exceeds threshold

Treatment Outcomes

Phototherapy [19]

• Efficacy: Reduces bilirubin 30-50% within 24-48 hours in most cases
• Success rate: 90-95% of infants respond adequately without exchange transfusion
• Safety: Excellent long-term safety; no adverse neurodevelopmental outcomes
• LED vs conventional: Equivalent efficacy; LED preferred (higher irradiance, less heat, longer lifespan)

Exchange Transfusion [20]

• Efficacy: Immediate 50-60% bilirubin reduction; equilibrates to 25-40% reduction after 1-2 hours
• Success rate: > 95% prevent kernicterus when performed before neurological signs develop
• Morbidity: 5-12% significant adverse events (thrombocytopenia, infection, NEC, electrolyte disturbances)
• Mortality: 0.3-1% (mostly critically ill infants with underlying conditions)

Neurodevelopmental Outcomes

Kernicterus Survivors [2,3,22]

• Severe disability: 60-80% have choreoathetoid cerebral palsy, deafness, or severe intellectual disability
• Moderate disability: 10-20% have milder motor, hearing, or cognitive impairment
• Mild/no disability: less than 10% have normal or near-normal development
• Quality of life: Severely impaired; require lifelong care and support

Recent cohort study (India, 2021): [22]

• 65 survivors of acute bilirubin encephalopathy followed 2-5 years
• 75% had cerebral palsy (90% dystonic/choreoathetoid type)
• 68% had hearing impairment (54% profound bilateral sensorineural hearing loss)
• 42% had intellectual disability
• Predictors of poor outcome: Delayed presentation, delayed exchange transfusion, peak bilirubin > 30 mg/dL (510 μmol/L)

Peak Bilirubin and Neurodevelopmental Risk

Kernicterus risk by peak bilirubin (term infants, no risk factors): [4,5]

• less than 340 μmol/L (less than 20 mg/dL): Risk negligible
• 340-425 μmol/L (20-25 mg/dL): Risk less than 1%
• 425-510 μmol/L (25-30 mg/dL): Risk 1-5%

• 510 μmol/L (> 30 mg/dL): Risk 5-30%

Risk MUCH higher with:

• Prematurity (less than 35 weeks)
• Low albumin (less than 25 g/L)
• Acidosis, sepsis, haemolysis
• Delayed treatment

Prognostic Factors

Long-Term Monitoring

After Severe Hyperbilirubinaemia (Bilirubin > 340 μmol/L or Exchange Transfusion)

• Auditory: Auditory brainstem response (ABR) at 3 months; repeat if abnormal
• Developmental: Neurodevelopmental assessment at 6, 12, 18, 24 months
• Motor: Assess for cerebral palsy, dystonia, choreoathetosis
• Vision: Ophthalmology review if gaze abnormalities
• Early intervention: Physiotherapy, hearing aids, speech therapy if deficits identified

After ABO/Rh Haemolytic Disease

• Late anaemia: Check haemoglobin weekly for 4-6 weeks; transfusion if Hb less than 70-80 g/L [16]
• Reticulocyte count: Monitor for ongoing haemolysis

After Conjugated Hyperbilirubinaemia

• Depends on underlying cause
• Biliary atresia post-Kasai: Monitor liver function, growth, fat-soluble vitamins; assess for portal hypertension, transplant need [6]

---

Evidence & Guidelines

Key International Guidelines

NICE CG98: Jaundice in Newborn Babies Under 28 Days (2016, updated 2023) [7]

• Screening: Visual inspection at every assessment; measure bilirubin if jaundice suspected
• Treatment thresholds: Gestation-specific nomograms for phototherapy and exchange transfusion
• Prolonged jaundice: Measure conjugated bilirubin in all infants jaundiced > 14 days (term) or > 21 days (preterm)
• Conjugated hyperbilirubinaemia: Urgent referral if conjugated bilirubin ≥25 μmol/L

AAP Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn ≥35 Weeks (2022) [8]

• Universal screening: Predischarge bilirubin measurement (visual assessment unreliable)
• Risk stratification: Use Bhutani nomogram to plot bilirubin by hour of life; identify high-risk zone
• Treatment thresholds: Hour-specific nomograms; lower thresholds for neurotoxicity risk factors
• Follow-up: Based on risk zone and feeding method; breastfed infants require earlier follow-up
• G6PD screening: Recommend in high-risk populations (Mediterranean, Middle Eastern, African, Asian)

Canadian Paediatric Society: Guidelines for Detection, Management and Prevention of Hyperbilirubinemia (2020)

• Emphasizes universal predischarge bilirubin screening
• Risk assessment using nomograms
• Gestation-specific treatment thresholds

Landmark Studies & Systematic Reviews

Phototherapy Efficacy

Cochrane Review: Phototherapy for neonatal jaundice (2023) [19]

• Evidence: High-quality evidence that phototherapy reduces severe hyperbilirubinaemia and exchange transfusion need
• LED vs conventional: LED phototherapy equally effective with advantages (higher irradiance, less heat, lower energy consumption)
• Intensive vs conventional: Intensive phototherapy (multiple lights, higher irradiance) more effective for rapidly rising bilirubin

Maisels & McDonagh. N Engl J Med 2008 [23]

• Seminal review of phototherapy mechanisms and efficacy
• Phototherapy reduces bilirubin 30-50% in 24-48 hours
• Dose-response relationship: Higher irradiance and greater surface area exposure = greater efficacy

Kernicterus Epidemiology & Prevention

Bhutani et al. J Perinatol 2004 [4]

• Described hour-specific bilirubin nomogram (Bhutani curve) for kernicterus risk stratification
• Pre-discharge risk assessment reduces readmission and severe hyperbilirubinaemia
• Systematic approach to screening and follow-up virtually eliminates kernicterus

Olusanya et al. Lancet Child Adolesc Health 2018 [1]

• Global burden: Estimated 481,000 infants develop severe hyperbilirubinaemia annually; 114,000 die; 63,000 survive with moderate-severe disability
• Vast majority in low- and middle-income countries (sub-Saharan Africa, South Asia)
• G6PD deficiency major contributor in endemic areas

Wickremasinghe et al. Semin Perinatol 2022 [5]

• Kernicterus incidence in high-income countries: 0.4-2.7 per 100,000 (dramatic reduction from 1:10,000 in pre-phototherapy era)
• Residual cases: Late presentation, missed diagnosis, home births, discharge before jaundice peak

Acute Bilirubin Encephalopathy Outcomes

Kumar et al. Early Hum Dev 2021 [22]

• Retrospective cohort of 65 survivors of acute bilirubin encephalopathy (India)
• 75% cerebral palsy, 68% hearing impairment, 42% intellectual disability
• Predictors of poor outcome: Peak bilirubin > 30 mg/dL (510 μmol/L), delayed exchange transfusion
• Emphasizes critical importance of early recognition and treatment

Kang et al. Ann Clin Transl Neurol 2020 [24]

• MRI findings in acute bilirubin encephalopathy: Globus pallidus and subthalamic nucleus T1 hyperintensity
• Early MRI abnormalities predict long-term motor and hearing outcomes

Immune Haemolytic Disease

Rh Disease Prevention

• Anti-D immunoglobulin (RhIG) prophylaxis at 28 and 34 weeks + postpartum: > 99% prevention of Rh sensitization [16]
• Virtually eliminated severe Rh disease in high-income countries
• Residual cases: Missed prophylaxis, undocumented Rh status, immigration from countries without routine prophylaxis

ABO Incompatibility

• Most common immune cause of neonatal jaundice (mother O, baby A/B)
• Usually mild-moderate (DAT-positive in 60-70%, but only 10-15% require phototherapy) [16]
• IVIG reduces exchange transfusion need by ~50% (NNT = 3-4) [21]

G6PD Deficiency

Olusanya et al. Pediatrics 2016 [11]

• G6PD deficiency affects ~400 million people worldwide (highest prevalence in sub-Saharan Africa, Mediterranean, Middle East, Southeast Asia)
• Major cause of severe neonatal jaundice and kernicterus in endemic areas
• Newborn screening recommended in high-prevalence populations

Biliary Atresia & Conjugated Hyperbilirubinaemia

Hartley et al. Lancet 2009 [6]

• Kasai portoenterostomy: Success rate 60-80% if performed less than 60 days; drops to less than 25% after 90 days
• Long-term outcomes: Even with successful Kasai, 50-70% require liver transplantation by adolescence
• Stool colour screening: Taiwan national programme reduced delayed diagnosis; infants diagnosed earlier had better outcomes

Quality of Evidence Summary

---

Patient & Family Information

What is Neonatal Jaundice?

Jaundice is yellowing of the skin and whites of the eyes caused by a yellow substance called bilirubin. Bilirubin is made when red blood cells break down naturally. Newborn babies often have jaundice because:

• Their livers are still learning to remove bilirubin efficiently
• They have more red blood cells than adults
• Their red blood cells don't last as long

More than half of all babies develop some jaundice in the first week of life. Most jaundice is harmless and goes away on its own.

When is Jaundice Harmful?

If bilirubin levels get very high, it can sometimes harm the brain. This is rare when jaundice is spotted early and treated. We monitor your baby carefully to make sure bilirubin stays at a safe level.

How is Jaundice Measured?

We check bilirubin levels using:

1. Skin device (painless): A small handheld device placed on your baby's forehead or chest
2. Blood test: A small blood sample from your baby's heel or hand (if the skin test shows high levels)

When to Seek Help Urgently

Contact your midwife, health visitor, or GP immediately if your baby:

• Develops jaundice in the first 24 hours of life
• Has jaundice that is getting worse or spreading down the body
• Is very sleepy or difficult to wake for feeds
• Is feeding poorly (fewer than 8 feeds in 24 hours)
• Has pale, chalky-white poo or very dark wee
• Is still jaundiced after 14 days (2 weeks) if born at term, or 21 days (3 weeks) if born early

What is Phototherapy ("Light Treatment")?

Phototherapy uses special blue lights to help break down bilirubin in your baby's skin. It is very safe and effective.

What happens during phototherapy:

• Your baby lies in a cot or incubator under blue lights
• They will wear only a nappy and eye shields (to protect their eyes)
• You can still feed and cuddle your baby (we'll take breaks from the lights)
• Your baby may have more frequent, looser poos (this is normal)

How long does it take?

• Usually 1-2 days
• We check bilirubin levels every few hours to see how well it's working

Is phototherapy safe?

• Yes, very safe
• Used for millions of babies worldwide for over 50 years
• No long-term side effects

What Can I Do to Help?

Feed your baby frequently:

• Aim for at least 8-12 feeds in 24 hours
• Frequent feeding helps your baby poo more, which removes bilirubin from the body
• Wake your baby for feeds if they are very sleepy

Continue breastfeeding:

• Breastfeeding is safe and recommended, even if your baby has jaundice
• Sometimes breastfed babies have jaundice for a bit longer (this is usually harmless)
• Get help with breastfeeding if you're having difficulties

Watch for warning signs (listed above) and contact your healthcare team if concerned

What is Exchange Transfusion?

In very rare cases (less than 1 in 1,000 babies), bilirubin levels are so high that phototherapy alone is not enough. In this situation, doctors may recommend an exchange transfusion. This procedure:

• Removes your baby's blood and replaces it with donor blood
• Quickly lowers bilirubin to a safe level
• Is done in the neonatal intensive care unit (NICU)
• Takes 2-4 hours

Exchange transfusion is only done when absolutely necessary to protect your baby's brain.

What About Pale Poo?

Normal poo colours in newborns:

• Mustard yellow (breastfed babies)
• Yellow-green or brown (formula-fed babies)
• Dark green/black in the first few days (meconium—the first poo)

Abnormal poo colour (requires urgent assessment):

• Chalky white, pale yellow, or grey poo

If your baby has pale poo, contact your doctor immediately. It may indicate a liver or bile duct problem that needs urgent investigation and treatment.

Will Jaundice Harm My Baby?

In most cases, no. Mild jaundice is normal and harmless. With careful monitoring and treatment when needed, serious complications are very rare in the UK and other countries with good healthcare.

If bilirubin gets very high and is not treated, it can cause brain damage (called kernicterus). This is why we monitor jaundice carefully and treat it early if needed. Kernicterus is now extremely rare in the UK because we have good screening and treatment.

Follow-Up After Going Home

• Your midwife or health visitor will check your baby after you go home
• They will look at your baby's skin and ask about feeding and poo
• If jaundice seems to be getting worse, they will arrange for a bilirubin test
• Keep all follow-up appointments

Questions to Ask Your Healthcare Team

• What is my baby's bilirubin level?
• Does my baby need treatment?
• How often will bilirubin be checked?
• When can we go home?
• What should I watch for at home?
• When is the next follow-up appointment?

Resources & Support

• NHS: Jaundice in Newborns: nhs.uk/conditions/jaundice-newborn
• NICE Patient Information: nice.org.uk/guidance/cg98/ifp
• Children's Liver Disease Foundation (CLDF): childliverdisease.org — Information on biliary atresia and stool colour charts
• Breastfeeding support: National Breastfeeding Helpline 0300 100 0212

---

References

Primary Guidelines

1. Olusanya BO, Kaplan M, Hansen TWR. Neonatal hyperbilirubinaemia: a global perspective. Lancet Child Adolesc Health. 2018;2(8):610-620. doi:10.1016/S2352-4642(18)30139-1. PMID: 30119720

2. Shapiro SM. Bilirubin toxicity in the developing nervous system. Pediatr Neurol. 2003;29(5):410-421. doi:10.1016/j.pediatrneurol.2003.09.011. PMID: 14684236

3. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage—mechanisms and management approaches. N Engl J Med. 2013;369(21):2021-2030. doi:10.1056/NEJMra1308124. PMID: 24256380

4. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999;103(1):6-14. doi:10.1542/peds.103.1.6. PMID: 9917432

5. Wickremasinghe AC, Kuzniewicz MW, Newman TB. Neonatal hyperbilirubinemia. Semin Perinatol. 2022;46(5):151581. doi:10.1016/j.semperi.2022.151581. PMID: 35339281

Clinical Guidelines

6. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet. 2009;374(9702):1704-1713. doi:10.1016/S0140-6736(09)60946-6. PMID: 19914515

7. National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days (CG98). 2016, updated 2023. Available at: nice.org.uk/guidance/cg98

8. Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859. PMID: 35927462

Pathophysiology & Risk Factors

9. Hegyi T, Kleinfeld A, Huber A, et al. Neonatal hyperbilirubinemia and the role of unbound bilirubin. J Matern Fetal Neonatal Med. 2022;35(25):8106-8114. doi:10.1080/14767058.2021.1993804. PMID: 34957902

10. Wennberg RP, Ahlfors CE, Bhutani VK, et al. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics. 2006;117(2):474-485. doi:10.1542/peds.2005-0395. PMID: 16452368

11. Olusanya BO, Emokpae AA, Zamora TG, et al. Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr. 2014;103(11):1102-1109. doi:10.1111/apa.12735. PMID: 25039710

12. Dobbs RH, Cremer RJ. Phototherapy. Arch Dis Child. 1975;50(11):833-836. PMID: 1106351

13. Watchko JF. Hyperbilirubinemia and bilirubin toxicity in the late preterm infant. Clin Perinatol. 2006;33(4):839-852. doi:10.1016/j.clp.2006.09.002. PMID: 17148008

14. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333(18):1171-1175. doi:10.1056/NEJM199511023331802. PMID: 7565971

15. Gartner LM, Herschel M. Jaundice and breastfeeding. Pediatr Clin North Am. 2001;48(2):389-399. doi:10.1016/s0031-3955(08)70032-6. PMID: 11339159

16. Murray NA, Roberts IAG. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F83-F88. doi:10.1136/adc.2005.076794. PMID: 17337672

17. Christensen RD, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia. Pediatrics. 2010;125(1):120-125. doi:10.1542/peds.2009-0897. PMID: 20008423

Investigations & Monitoring

18. Maisels MJ, Engle WD, Wainer S, et al. Transcutaneous bilirubin levels in an outpatient and office population. J Perinatol. 2011;31(9):621-624. doi:10.1038/jp.2011.14. PMID: 21330996

Treatment & Interventions

19. Malwade US, Jardine LA. Phototherapy for neonatal jaundice. Cochrane Database Syst Rev. 2023;8(8):CD001520. doi:10.1002/14651858.CD001520.pub3. PMID: 37615230

20. Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics. 1997;99(5):E7. doi:10.1542/peds.99.5.e7. PMID: 9113960

21. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88(1):F6-F10. doi:10.1136/fn.88.1.f6. PMID: 12496219

Outcomes & Prognosis

22. Kumar V, Garg P, Sharma A, et al. Childhood neurodevelopmental outcomes of survivors of acute bilirubin encephalopathy: A retrospective cohort study. Early Hum Dev. 2021;158:105396. doi:10.1016/j.earlhumdev.2021.105396. PMID: 33990043

23. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008;358(9):920-928. doi:10.1056/NEJMct0708376. PMID: 18305267

24. Kang W, Wang A, Liu Q, et al. Early prediction of adverse outcomes in infants with acute bilirubin encephalopathy. Ann Clin Transl Neurol. 2020;7(7):1141-1146. doi:10.1002/acn3.51091. PMID: 32495505

Additional Resources

• Bhutani VK, Committee on Fetus and Newborn, American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2011;128(4):e1046-e1052. PMID: 21949152

• UpToDate: Unconjugated Hyperbilirubinemia in the Newborn (Maisels MJ, McDonagh AF)

• BMJ Best Practice: Neonatal Jaundice

• Children's Liver Disease Foundation: childliverdisease.org

---